|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Schering-Plough Indonesia Tbk, PT
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Schering-Plough Indonesia Tbk, PT Headquarters 10/F Mayapada Tower Jln Jend Sudirman Kav 28; Jakarta; Jakarta; 12920 Legal Address 10/F Wisma Bank Dharmala Jln Jend Sudirman Kav 28; Jakarta; Jakarta; 12920 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : ID1000088800 Financial Auditors: Tanudiredja, Wibisana & Rekan (2011) Incorporation Date: November 1, 1972 Total Employees: 338 Tel: (62 21) 5225452 |
|
Company Description |
| PT Schering-Plough Indonesia Tbk (SCPI)'s activities are comprised of processing and promoting of pharmaceutical products for human and animal consumption, toiletries, cosmetics, household and related products SCPI was established on November 01, 1972 and listed on the Jakarta Stock Exchange on June 08, 1990. The company is part of the Schering-Plough International Inc.,a global science-based health care company with leading prescription, consumer and animal health products. Through internal research | ||
|
||
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues increased with 0.52%, from IDR 236,150,597 thousands to IDR 237,386,635 thousands. Operating Results decreased from IDR 24,613,372 thousands to IDR -1,672,949 thousands. The results of the period reached IDR -17,611,080 thousands at the end of the period against IDR 8,217,669 thousands last year. Return on equity (Net income/Total equity) went from 40.40% to -92.77%, the Return On Asset (Net income / Total Asset) went from 2.39% to -4.01% and the Net Profit Margin (Net Income/Net Sales) went from 3.48% to -7.42% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 2213.30% compared to 1590.54% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 0.92 to 2.86 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Q3C (cons) |
2012 Q2C (cons) |
|
 | ||
| Non-Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
439,138,880 |
366,749,536 |
| ||
Current Assets |
301,647,584 |
251,540,496 |
| ||
Total Liabilities |
420,155,680 |
355,545,696 |
| ||
Shareholders Equity |
18,983,224 |
11,203,833 |
| ||
Current Liabilities |
105,643,816 |
92,932,112 |
| ||
| * All the accounts are in IDR. | ||
Income Statement
| ||
Total Operating Revenue |
237,386,635 |
149,046,658 |
| ||
Operational Profit (Loss) |
-1,672,949 |
1,196,475 |
| ||
Net Profit (Loss) |
-17,611,080 |
-10,392,979 |
| ||
| * All the accounts are in IDR. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
-4.01% |
-2.83% |
| ||
Annualised Return on Assets (ROA) |
-5.35% |
-5.66% |
| ||
Return on Equity (ROE) |
-92.77% |
-92.76% |
| ||
Annualised Return on Equity (ROE) |
-123.69% |
-185.52% |
| ||
Return on Sales (ROS) |
-7.88% |
-7.53% |
| ||
Return on Capital |
-5.49% |
-3.97% |
| ||
Gross Profit Margin |
30.4% |
31.59% |
| ||
Operating Profit Margin |
-5.96% |
-5.69% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
1.77x |
1.37x |
| ||
Inventory Turnover |
1.36x |
0.86x |
| ||
Current asset turnover |
0.74x |
0.55x |
| ||
Fixed-asset turnover |
1.63x |
1.20x |
| ||
Asset Turnover |
0.51x |
0.38x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
-1,672,937 |
1,196,483 |
| ||
EBITDA |
527,771 |
3,253,438 |
| ||
Enterprise value |
437,110,553 |
397,259,302 |
| ||
Enterprise Value / EBITDA |
828.22 |
122.10 |
| ||
Bookvalue (BV) |
137,054,848 |
116,272,992 |
| ||
Net Cash |
-89,470,337 |
-88,514,870 |
| Liquidity Ratios | ||
| ||
Current Ratio |
285.53% |
270.67% |
| ||
Quick ratio |
177.47% |
152.52% |
| ||
Doom's day ratio |
15.31% |
4.75% |
| Leverage Ratios | ||
| ||
Leverage ratio |
2,313.3% |
3,273.43% |
| ||
Interest Coverage Ratio |
-55.14% |
142.64% |
| ||
Debt to equity |
2,213.3% |
3,173.43% |
| ||
Debt to total assets |
95.68% |
96.95% |
| ||
Long Term Debt to Capital |
98.87% |
98.65% |
| ||
Debt / Enterprise Value |
69.11% |
63.05% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
286.49 |
46.47 |
| ||
Price/Book Ratio |
1.10 |
1.30 |
| ||
Market Cap / Net cash |
-1.69 |
-1.71 |
| Trend Ratios | ||
| ||
Revenue Trend |
97.33% |
91.75% |
| ||
Net Income Trend |
-214.31% |
-133.61% |
| ||
Operating Income Trend |
-6.8% |
6.7% |
| ||
 |